Recombinant DNA-produced α1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with α1-antitrypsin deficiency

R. C. Hubbard, N. G. McElvaney, S. E. Sellers, J. T. Healy, D. B. Czerski, Ronald Crystal

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

α1-Antitrypsin (α1AT) deficiency is characterized by insufficient amounts of α1AT to protect the lower respiratory tract from neutrophil elastase, resulting in emphysema. Yeast-produced recombinant α1AT (rAAT) has normal antielastase function but is associated with high renal clearance, thus obviating chronic intravenous administration. As an alternative, we evaluated aerosol administration of rAAT to α1AT-deficient individuals. After aerosol administration of single doses of 10-200 mg of rAAT, epithelial lining fluid (ELF) α1AT antineutrophil elastase defenses were augmented in proportion to the dose of rAAT administered. ELF α1AT levels and antineutrophil elastase capacity 4 h after 200 mg rAAT aerosol were increased 40-fold over preaerosol levels, and were fivefold increased over baseline at 24 h after aerosol administration. rAAT was detectable in serum after aerosol, indicating that the lower respiratory tract epithelium may be permeable to rAAT, and that aerosolized rAAT is capable of gaining access to lung interstitium. No adverse clinical effects were noted. These observations demonstrate that aerosol administration of rAAT is safe and results in significant augmentation of lung antineutrophil elastase defenses, suggesting this method is a feasible approach to therapy. Because this approach is clinically unproven, further studies will be necessary to establish the long-term clinical efficacy of aerosol therapy in α1AT deficiency.

Original languageEnglish
Pages (from-to)1349-1354
Number of pages6
JournalJournal of Clinical Investigation
Volume84
Issue number4
Publication statusPublished - 1 Jan 1989
Externally publishedYes

Fingerprint

Recombinant DNA
Pancreatic Elastase
Aerosols
Respiratory System
Respiratory Mucosa
Lung
Leukocyte Elastase
Emphysema
Intravenous Administration
Yeasts
Kidney
Therapeutics
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Recombinant DNA-produced α1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with α1-antitrypsin deficiency. / Hubbard, R. C.; McElvaney, N. G.; Sellers, S. E.; Healy, J. T.; Czerski, D. B.; Crystal, Ronald.

In: Journal of Clinical Investigation, Vol. 84, No. 4, 01.01.1989, p. 1349-1354.

Research output: Contribution to journalArticle

@article{bb4f7a9e0d07459b91d7b2534426e24e,
title = "Recombinant DNA-produced α1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with α1-antitrypsin deficiency",
abstract = "α1-Antitrypsin (α1AT) deficiency is characterized by insufficient amounts of α1AT to protect the lower respiratory tract from neutrophil elastase, resulting in emphysema. Yeast-produced recombinant α1AT (rAAT) has normal antielastase function but is associated with high renal clearance, thus obviating chronic intravenous administration. As an alternative, we evaluated aerosol administration of rAAT to α1AT-deficient individuals. After aerosol administration of single doses of 10-200 mg of rAAT, epithelial lining fluid (ELF) α1AT antineutrophil elastase defenses were augmented in proportion to the dose of rAAT administered. ELF α1AT levels and antineutrophil elastase capacity 4 h after 200 mg rAAT aerosol were increased 40-fold over preaerosol levels, and were fivefold increased over baseline at 24 h after aerosol administration. rAAT was detectable in serum after aerosol, indicating that the lower respiratory tract epithelium may be permeable to rAAT, and that aerosolized rAAT is capable of gaining access to lung interstitium. No adverse clinical effects were noted. These observations demonstrate that aerosol administration of rAAT is safe and results in significant augmentation of lung antineutrophil elastase defenses, suggesting this method is a feasible approach to therapy. Because this approach is clinically unproven, further studies will be necessary to establish the long-term clinical efficacy of aerosol therapy in α1AT deficiency.",
author = "Hubbard, {R. C.} and McElvaney, {N. G.} and Sellers, {S. E.} and Healy, {J. T.} and Czerski, {D. B.} and Ronald Crystal",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "84",
pages = "1349--1354",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "4",

}

TY - JOUR

T1 - Recombinant DNA-produced α1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with α1-antitrypsin deficiency

AU - Hubbard, R. C.

AU - McElvaney, N. G.

AU - Sellers, S. E.

AU - Healy, J. T.

AU - Czerski, D. B.

AU - Crystal, Ronald

PY - 1989/1/1

Y1 - 1989/1/1

N2 - α1-Antitrypsin (α1AT) deficiency is characterized by insufficient amounts of α1AT to protect the lower respiratory tract from neutrophil elastase, resulting in emphysema. Yeast-produced recombinant α1AT (rAAT) has normal antielastase function but is associated with high renal clearance, thus obviating chronic intravenous administration. As an alternative, we evaluated aerosol administration of rAAT to α1AT-deficient individuals. After aerosol administration of single doses of 10-200 mg of rAAT, epithelial lining fluid (ELF) α1AT antineutrophil elastase defenses were augmented in proportion to the dose of rAAT administered. ELF α1AT levels and antineutrophil elastase capacity 4 h after 200 mg rAAT aerosol were increased 40-fold over preaerosol levels, and were fivefold increased over baseline at 24 h after aerosol administration. rAAT was detectable in serum after aerosol, indicating that the lower respiratory tract epithelium may be permeable to rAAT, and that aerosolized rAAT is capable of gaining access to lung interstitium. No adverse clinical effects were noted. These observations demonstrate that aerosol administration of rAAT is safe and results in significant augmentation of lung antineutrophil elastase defenses, suggesting this method is a feasible approach to therapy. Because this approach is clinically unproven, further studies will be necessary to establish the long-term clinical efficacy of aerosol therapy in α1AT deficiency.

AB - α1-Antitrypsin (α1AT) deficiency is characterized by insufficient amounts of α1AT to protect the lower respiratory tract from neutrophil elastase, resulting in emphysema. Yeast-produced recombinant α1AT (rAAT) has normal antielastase function but is associated with high renal clearance, thus obviating chronic intravenous administration. As an alternative, we evaluated aerosol administration of rAAT to α1AT-deficient individuals. After aerosol administration of single doses of 10-200 mg of rAAT, epithelial lining fluid (ELF) α1AT antineutrophil elastase defenses were augmented in proportion to the dose of rAAT administered. ELF α1AT levels and antineutrophil elastase capacity 4 h after 200 mg rAAT aerosol were increased 40-fold over preaerosol levels, and were fivefold increased over baseline at 24 h after aerosol administration. rAAT was detectable in serum after aerosol, indicating that the lower respiratory tract epithelium may be permeable to rAAT, and that aerosolized rAAT is capable of gaining access to lung interstitium. No adverse clinical effects were noted. These observations demonstrate that aerosol administration of rAAT is safe and results in significant augmentation of lung antineutrophil elastase defenses, suggesting this method is a feasible approach to therapy. Because this approach is clinically unproven, further studies will be necessary to establish the long-term clinical efficacy of aerosol therapy in α1AT deficiency.

UR - http://www.scopus.com/inward/record.url?scp=0024417082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024417082&partnerID=8YFLogxK

M3 - Article

C2 - 2794066

AN - SCOPUS:0024417082

VL - 84

SP - 1349

EP - 1354

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 4

ER -